Diabetologia

, Volume 51, Issue 10, pp 1933–1934 | Cite as

Mediterranean diet in type 2 diabetes

  • F. J. Basterra-Gortari
  • M. A. Martínez-González
Letter

Keywords

Diabetes Monounsaturated fat Olive oil Polyphenols 

Abbreviations

MMD

modified Mediterranean diet

To the Editor: We read with great interest the article by Fraser et al. [1], which reported that patients randomised to receive a modified Mediterranean diet (MMD) showed greater reductions in alanine aminotransferase levels at 6 and 12 months compared with those who received the 2003 American Diabetes Association diet or the low glycaemic index diet.

Macronutrient intakes (assessed using a food frequency questionnaire) for the three different diet groups at 6 months after randomisation are shown in Table 2 of the paper [1]; however, no data are provided on the consumption of different food groups. This information is needed to appraise the practical implications of the results. Some food groups (vegetables, legumes, fruit and nuts, cereals, olive oil, wine and fish) are characteristic of the Mediterranean diet and have been frequently used in conjunction with non-characteristic elements (meat, dairy), to give a modified functional definition [2]. The provision of information on food groups would clarify how comparable the study by Fraser et al. [1] is to other investigations of this subject.

Several mechanisms, involving fibre, antioxidants or polyphenols, are thought to be responsible for the inverse association between the Mediterranean diet and the risks of the metabolic syndrome and type 2 diabetes or its complications [3]. In addition, excessive accumulation of triacylglycerol in hepatocytes, which is the hallmark of non-alcoholic fatty liver disease, is associated with insulin resistance [4]. Given that certain foods characteristic of a Mediterranean diet are high in polyphenols (e.g. virgin olive oil, fruit and vegetables, red wine), it may be speculated that differences in levels of these constituents across the three diets, rather than the total amount of carbohydrate or fat, are responsible for the greater reductions in the alanine aminotransferase levels observed in the MMD group at 6 and 12 months. In addition to the beneficial effects of a Mediterranean diet demonstrated in the PREDIMED (Prevención con Dieta Mediterránea) trial [5], mentioned in the paper by Fraser et al. [1], a large Spanish prospective dynamic cohort (n = 13,380), included in the SUN (Seguimiento Universidad de Navarra) study, has recently shown that a Mediterranean-type diet is able to substantially reduce the risk of type 2 diabetes [6] and the metabolic syndrome [7]. It is therefore possible that the evidence provided by Fraser et al. [1] suggesting that a Mediterranean diet can offer substantial benefit on liver steatosis is connected to these reported reductions in risk [6, 7].

In addition to emerging evidence that Mediterranean diets have a positive effect on cardiovascular epidemiology [8], a classical Mediterranean diet may be the ideal model for the prevention of diabetes [6] and its complications, including some consequences of non-alcoholic fatty liver disease, in type 2 diabetic individuals, such as chronic kidney disease and retinopathy [9].

Notes

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

References

  1. 1.
    Fraser A, Abel R, Lawlor DA, Fraser D, Elhayany A (2008) A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia doi: 10.1007/s00125-008-1049-1
  2. 2.
    Trichopoulou A, Costacou T, Bamia C, Trichopoulos D (2003) Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 348:2599–2608PubMedCrossRefGoogle Scholar
  3. 3.
    Schröder H (2007) Protective mechanisms of the Mediterranean diet in obesity and type 2 diabetes. J Nutr Biochem 18:149–160PubMedCrossRefGoogle Scholar
  4. 4.
    Abdelmalek MF, Diehl AM (2007) Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 91:1125–1149PubMedCrossRefGoogle Scholar
  5. 5.
    Zazpe I, Sanchez-Tainta A, Estruch R et al (2008) A large randomized individual and group intervention conducted by registered dietitians increased adherence to Mediterranean-type diets: the PREDIMED study. J Am Diet Assoc 108:1134–1144PubMedCrossRefGoogle Scholar
  6. 6.
    Martinez-Gonzalez MA, de la Fuente-Arrillaga C, Nunez-Cordoba JM et al (2008) Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ 336:1348–1351PubMedCrossRefGoogle Scholar
  7. 7.
    Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A et al (2007) Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. Diabetes Care 30:2957–2959PubMedCrossRefGoogle Scholar
  8. 8.
    Martínez-González MA, Sánchez-Villegas A (2004) The emerging role of Mediterranean diets in cardiovascular epidemiology: monounsaturated fats, olive oil, red wine or the whole pattern? Eur J Epidemiol 19:9–13PubMedCrossRefGoogle Scholar
  9. 9.
    Targher G, Bertolini L, Rodella S et al (2008) Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51:444–450PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • F. J. Basterra-Gortari
    • 1
    • 2
  • M. A. Martínez-González
    • 1
  1. 1.Department of Preventive Medicine, Medical School-University ClinicUniversity of NavarraPamplonaSpain
  2. 2.Department of EndocrinologyNavarra HospitalPamplonaSpain

Personalised recommendations